Eric Raymond

A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.

M. Ducreux, E. Raymond, E. Baudin, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

C. Tournigand, E. Raymond, A. Gramont, 1997, European journal of cancer.

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.

S. Novello, R. Henriksson, E. Raymond, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers

E. Raymond, C. Buquet-Fagot, J. Mester, 1997, Anti-cancer drugs.

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

E. Raymond, M. Campone, F. Calvo, 2009, British Journal of Cancer.

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.

E. Raymond, M. Campone, J. Armand, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

E. Raymond, F. Goldwasser, P. Cottu, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

E. Raymond, R. Kurzrock, G. Schwartz, 2012, British Journal of Cancer.